Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, announced the closing of a $20 million equity investment, at $4.03 per share, by Betta Pharmaceuticals (SZ300558) bringing the total received to $35M. Read More »
While the development of COVID-19 vaccines is still in the early stages, a set of data from Moderna shows promising signs of efficacy, Managed Healthcare reported. Read More »
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Read More »
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). Read More »
Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma. Read More »
CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Read More »
Within a week of FDA approval, MAVENCLAD has formulary coverage with one of the leading pharmacy benefit managers in the U.S. Read More »
New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy Read More »
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat OFF episodes (the re-emergence or worsening of Parkinson’s symptoms otherwise controlled by medications) experienced by people living with Parkinson’s disease (PD). Read More »
Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing Read More »
SOPHiA GENETICS, a leading health tech company, announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. Read More »
Ludovic Fenaux to lead Vertex’s expanding International organization and Simon Bedson announces retirement Read More »
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD).. Read More »
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S.Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment of sickle cell disease pending the resolution of certain questions that will be provided by the FDA as part of its review of the IND. Read More »
"This approval marks an important milestone for the mental health community in Canada, where few approved treatment options are available to adolescents with bipolar depression" Read More »
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March Read More »
Orfadin, a drug used to treat a condition causing kidney and liver damage, has now received the FDA’s go-ahead for once-a-day use, cutting its dosing frequency in half. Read More »
Abbott recently announced the initiation of a pivotal clinical study based in the United States that will assess the safety and efficacy of a modified version of its Amplatzer device. Read More »
Newly compiled data from the Blue Cross Blue Shield Association indicates that the nation — particularly the state of Massachusetts — has substantially lowered the number of outpatient prescriptions for antibiotics, association sources announced recently from Boston. Read More »
Alerts Sign-up